Answers are grounded in this paper and cite their sources.
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is frequently fatal, and end-of-life symptom management often involves noninvasive respiratory support and pharmacological approaches, including opioids. We aimed to describe temporal patterns of end-of-life respiratory support, with a focus on high-flow nasal cannula (HFNC) adoption, and to examine modality-specific patterns of opioid use among in-hospital decedents with AE-IPF. Repeated cross-sectional study using a Japanese nationwide claims database (fiscal years 2016–2021) was conducted. We classified end-of-life respiratory support (HFNC and other modalities) and identified opioid usage during the last two hospital days. Annual proportions were described overall and by modality; modality-specific slopes were estimated using mixed-effects logistic regression and fixed-effect models, including a year-by-modality interaction, with odds ratios (ORs) per year with 95% confidence intervals (CIs). Robustness was evaluated using sensitivity analyses and multiple imputations. Among 2,292 in-hospital decedents with AE-IPF, HFNC use in the last hospital days increased from 16.7% in 2016 to 41.2% in 2021 (4.9 percentage points; 95% CI, 3.8–6.0). Overall, opioid use changed minimally (51.0%–54.5%; 1.2 percentage points; 95% CI, 0.0–2.5). In the mixed-effects model, the overall trend remained flat (OR, 1.03; 95% CI, 0.96–1.11). Opioid use increased with noninvasive ventilation (NIV) (OR, 1.17; 95% CI, 1.04–1.31) and remained high but was stable or slightly downward with HFNC (OR, 0.97; 95% CI, 0.88–1.08). These results are consistent with those of the sensitivity analyses. HFNC has become the predominant end-of-life respiratory support modality among AE-IPF in-hospital decedents. Opioid use patterns have diverged by modality, increasing with NIV and remaining high but stable to slightly declining with HFNC. This modality-specific divergence may reflect heterogeneity in end-of-life care processes, highlighting the importance of structured symptom assessment and multidisciplinary symptom management strategies in end-of-life care for AE-IPF. Not applicable.
No takes yet. Share an insight, caveat, or question.
Uchida et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: